Erick Lucera - Mar 31, 2025 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Chief Financial Officer
Signature: /s/ Ron Caponigro, Attorney-in-Fact
Stock symbol: DYN
Transactions as of: Mar 31, 2025
Transactions value $: $0
Form type: 4
Date filed: 4/1/2025, 04:33 PM
Previous filing: Mar 28, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DYN	Common Stock	Award	$0	+66.1K		$0.00	66.1K	Mar 31, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DYN	Stock Option (Right to Buy)	Award	$0	+215K		$0.00	215K	Mar 31, 2025	Common Stock	215K	$10.46	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of shares of Common Stock issuable under 66,100 restricted stock units ("RSU"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest as to 25% of the shares in equal annual installments over four years with the first installment vesting on March 31, 2026, subject to continuous service.
F2	The option was granted on March 31, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 31, 2026, and the remainder vesting in 12 equal quarterly installments thereafter, subject to continuous service.